Alejandra Carvajal - 13 Jan 2023 Form 4 Insider Report for Mersana Therapeutics, Inc. (MRSN)

Signature
/s/Alejandra Carvajal
Issuer symbol
MRSN
Transactions as of
13 Jan 2023
Net transactions value
-$4,489
Form type
4
Filing time
18 Jan 2023, 19:09:39 UTC
Previous filing
28 Apr 2022
Next filing
28 Apr 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRSN Common Stock Options Exercise $0 +2,500 +27% $0.000000 11,802 14 Jan 2023 Direct F1
transaction MRSN Common Stock Sale $4,489 -782 -6.6% $5.74 11,020 17 Jan 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRSN Stock option (right to buy) Award $0 +161,250 $0.000000 161,250 13 Jan 2023 Common Stock 161,250 $6.06 Direct F4
transaction MRSN Restricted stock unit Award $0 +35,833 $0.000000 35,833 13 Jan 2023 Common Stock 35,833 Direct F5, F6
transaction MRSN Restricted stock unit Options Exercise $0 -2,500 -25% $0.000000 7,500 14 Jan 2023 Common Stock 2,500 Direct F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022.
F2 Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy her tax withholding obligations and does not represent a discretionary trade by the Reporting Person.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The option shall vest in equal quarterly installments over four years from the date of grant.
F5 Each RSU represents the contingent right to receive one share of common stock of the Issuer.
F6 The RSUs shall vest in equal annual installments over four years from the date of grant.
F7 25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years.